Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.46 |
| ▸ | NPY4R | P50391 | 3/20 | 0.45 |
| ▸ | NPY1R | P25929 | 2/20 | 0.45 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570976 | 0.96 | NTMT1 (0.51) | NTMT1OPRM1OPRK1OPRD1NPFFR1 | |
| SCHEMBL21570973 | 0.96 | NTMT1 (0.51) | NTMT1OPRM1OPRK1OPRD1NPFFR1 | |
| SCHEMBL21571015 | 0.96 | NTMT1 (0.51) | NTMT1OPRM1OPRK1OPRD1NPFFR1 | |
| SCHEMBL21579316 | 0.96 | NTMT1 (0.51) | NTMT1OPRM1OPRK1OPRD1NPFFR1 | |
| SCHEMBL21570970 | 0.96 | NTMT1 (0.51) | NTMT1OPRM1OPRK1OPRD1NPFFR1 | |
| SCHEMBL21570990 | 0.92 | OPRM1 (0.48) | NTMT1OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL21570993 | 0.92 | OPRM1 (0.48) | NTMT1OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL21570988 | 0.92 | OPRM1 (0.48) | NTMT1OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL21570971 | 0.90 | NTMT1 (0.51) | NTMT1OPRM1OPRK1 | |
| SCHEMBL21570975 | 0.90 | NTMT1 (0.51) | NTMT1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | GNMT, PRMT1, PRMT5 | NTMT1 29/4885OPRM1 1865/4885OPRK1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.